title: Intravitreal therapies for non-neovascular age-related macular degeneration with intraretinal or subretinal fluid.
abstract: OBJECTIVE
  To evaluate the efficacy of intravitreal therapies in cases of atrophic age-related macular degeneration (AMD) with subretinal or intraretinal fluid.
  
  
  METHODS
  A retrospective review was made of the clinical charts of patients diagnosed with atrophic AMD with subretinal or intraretinal fluid. Fundus photographs and spectral-domain optical coherence tomography images were examined, and an analysis was made on the presence of fluid and its density. Neovascularisation was ruled out by fluorescein and/or indocyanine green angiography.
  
  
  RESULTS
  The study included 14 eyes from 13 patients with a mean age of 72.64 years and a mean follow-up of 80.5 weeks. Intraretinal fluid was observed in 6 eyes (42.9%), while subretinal fluid was shown in 8 eyes (57.1%), with high density in 4 eyes (28.5%), and low density in 4 eyes (28.5%). Snellen best-corrected visual acuity improved from 0.37 at baseline to 0.56 at the final visit (P=.002). Central subfield thickness (microns) significantly decreased (P<.001) from 291.0 at baseline to 228.9 at the final visit. Eight eyes received ranibizumab, 5eyes received bevacizumab, and one case received triamcinolone.
  
  
  CONCLUSIONS
  Cases of atrophic AMD may present with subretinal or intraretinal fluid in the absence Neovascularisation. Further studies are required to analyse the value of this finding as a risk factor of developing advanced forms of AMD, as well as the efficacy of intravitreal therapies.
authors.affiliation: Servicio de Oftalmología, Complejo Asistencial Universitario de León , León, España.
authors.forename: M
authors.initials: M
authors.lastname: Cuesta-Lasso
authors.affiliation: Serviço de Oftalmologia, Centro Hospitalar Entre Douro e Vouga, Santa María da Feira, Portugal.
authors.forename: A
authors.initials: A
authors.lastname: Vieira-Barros
authors.affiliation: Instituto de Investigaciones Sanitarias La Fe, Hospital Universitario y Politécnico La Fe, Valencia, España; RETICS RD160008 Enfermedades Oculares. Prevención, Detección precoz, Tratamiento y Rehabilitación de las Enfermedades Oculares, Madrid, España.
authors.forename: R
authors.initials: R
authors.lastname: Dolz-Marco
authors.affiliation: FISABIO Oftalmología Médica, Valencia, España.
authors.forename: M J
authors.initials: MJ
authors.lastname: Roig-Revert
authors.affiliation: Servicio de Oftalmología, Hospital Moisés Broggi, Sant Joan Despí, Barcelona, España.
authors.forename: J
authors.initials: J
authors.lastname: Badal
authors.affiliation: Servicio de Oftalmología, Hospital Moisés Broggi, Sant Joan Despí, Barcelona, España.
authors.forename: L
authors.initials: L
authors.lastname: Amselem
authors.affiliation: Facultad de Medicina, Universidad de Valencia, Valencia, España.
authors.forename: M
authors.initials: M
authors.lastname: Díaz-Llopis
authors.affiliation: Instituto de Investigaciones Sanitarias La Fe, Hospital Universitario y Politécnico La Fe, Valencia, España; RETICS RD160008 Enfermedades Oculares. Prevención, Detección precoz, Tratamiento y Rehabilitación de las Enfermedades Oculares, Madrid, España; Unidad de Mácula, Servicio de Oftalmología, Hospital Universitario y Politécnico La Fe, Valencia, España. Electronic address: rosadolzmarco@gmail.com.
authors.forename: R
authors.initials: R
authors.lastname: Gallego-Pinazo
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000068258:Bevacizumab / Q000008:administration & dosage* / Q000627:therapeutic use; D005122:Exudates and Transudates; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D000069579:Ranibizumab / Q000008:administration & dosage* / Q000627:therapeutic use; D012160:Retina / Q000473:pathology; D015593:Retinal Drusen / Q000209:etiology; D058471:Subretinal Fluid / Q000187:drug effects; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014221:Triamcinolone / Q000008:administration & dosage / Q000627:therapeutic use; D057135:Wet Macular Degeneration / Q000188:drug therapy* / Q000473:pathology
chemical_list: D020533:Angiogenesis Inhibitors; D014221:Triamcinolone; D000068258:Bevacizumab; D000069579:Ranibizumab
keywords: Degeneración macular asociada a la edad no neovascular; Fluido intrarretiniano; Fluido subretiniano; Intraretinal fluid; Intravitreal therapies; Non-neovascular age related macular degeneration; Spectral domain optical coherence tomography; Subretinal fluid; Terapias intravítreas; Tomografía de coherencia óptica de dominio espectral